- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01861730
Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)
April 6, 2018 updated by: Aeras
Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants
Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study of AERAS-404 Tuberculosis (TB) vaccine administered intramuscularly in Bacille Calmette-Guerin (BCG) primed infants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study in HIV-uninfected, HIV-unexposed, BCG-primed infants.
The study vaccine AERAS-404 or placebo will be administered without concomitant EPI vaccines (Cohorts 1 to 5, N = 159 subjects) and with concomitant EPI vaccines (Cohort 6, N = 70 subjects).
Study vaccine or placebo will be administered as a single dose (injection) at Study Day 0 ( ≥168 to ≤ 196 days of age, Cohorts 1 and 2), a 2-dose schedule at Study Day 0 (≥ 168 to ≤ 189 days of age) and Study Day 28 (Cohorts 3A and 3B) or a 3-dose schedule at Study Day 0 (≥ 84 to ≤ 98 days of age), Study Day 42 and Study Day 98 (Cohorts 4 and 5).
Subjects in Cohort 6 will receive the study vaccine or placebo at Study Day 0 (≥ 64 to ≤ 83 days of age), Study Day 28 (≥ 91 to ≤ 105 days of age), and Study Day 210 (≥ 273 to ≤ 287 days of age).
A cohort will enroll once safety in the previous cohort has been established.
AERAS-404 is an investigational vaccine manufactured by Sanofi Pasteur (SP) and Statens Serum Institute (SSI).
Study Type
Interventional
Enrollment (Actual)
243
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Worcester, South Africa
- South African TB Vaccine Initiative (SATVI)
-
-
Guateng
-
Johannesburg, Guateng, South Africa, 2091
- PHRU, Chris Hani Baragwanath Hospital
-
-
Hillbrow
-
Johannesburg, Hillbrow, South Africa, 2001
- Shandukani Research
-
-
Tygerberg
-
Cape Town, Tygerberg, South Africa, 7505
- KID-CRU, Tygerberg Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 6 months (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
INCLUSION CRITERIA
Age at time of entry:
Cohorts 1 to 6
- Cohorts 1 and 2: ≥ 168 to ≤ 196 days
- Cohorts 3A and 3B: ≥ 168 to ≤ 189 days
- Cohorts 4 and 5: ≥ 84 to ≤ 98 days (≥ 2 weeks after receipt of EPI vaccine doses at 10 weeks of age)
- Cohort 6 - coincident with EPI vaccine doses at 10 weeks of age (≥ 64 to ≤ 83 days of age)
- Source documentation of birth weight ≥ 2.5 kg.
- Documented BCG vaccination within 72 hours of birth.
- Documented receipt of all age-appropriate EPI vaccines, except Rotavirus, for Cohorts 4 to 6 (see Appendix II).
- Source documentation of a negative HIV status in the mother, from any time during pregnancy with this child through randomization.
- Documentation of infant HIV negative exposure or infection status with negative HIV ELISA and HIV DNA PCR tests.
- Parent or legal guardian able and willing to provide signed informed consent.
- Participant/parent/legal guardian able to attend all scheduled visits and to comply with all trial procedures.
EXCLUSION CRITERIA
- History of TB exposure in household or non-household contact.
- History/Evidence of TB disease or infection.
- Quantiferon positive.
- Prior TST test.
- Any one of Anemia, Neutropenia, Thrombocytopenia, SGPT (ALT), SGOT (AST) or Creatinine ≥ Grade 2
- Receipt of a live vaccine within 28 days prior to randomization.
- Receipt or planned receipt of any investigational vaccine.
- Known or suspected congenital immunodeficiency.
- Receipt of immunosuppressive therapy or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- Known or suspected autoimmune disease
- Hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances as the vaccine used in the trial.
- Participation in another clinical trial for an investigational product (IP).
- Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding randomization, contraindicating IM vaccination.
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]) within 24 hours prior to randomization.
Note: A subject may enroll after recovery from febrile illness if the subject is still within the age window.
- Systemic antibiotic use within 48 hours prior to randomization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo
1 Dose; Subject ≥ 168 to ≤ 196 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo
1 Dose; Subject ≥ 168 to ≤ 196 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo
2 Doses; Subject ≥ 168 to ≤ 189 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo
2 Doses; Subject ≥ 168 to ≤ 189 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo
3 Doses; Subject ≥ 84 to ≤ 98 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo
3 Doses; Subject ≥ 84 to ≤ 98 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
EXPERIMENTAL: Cohort 6 AERAS-404 (dose level pending) or Placebo
3 Doses; Subject ≥ 64 to ≤ 83 days of age
|
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant.
The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Names:
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigate the safety of AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants.
Time Frame: Subjects will be followed for up to 1 year and 4 months.
|
Adverse Events and Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study.
Solicited adverse events are captured 28 days post each vaccination.
Evaluation of the safety profile of AERAS-404 will be performed using data from all subjects who received at least one dose and has 7 days of safety data, and will be summarized by cohort and treatment group.
The number (percentage) of subjects with any adverse event (including solicited, unsolicited, and serious adverse events) will be summarized by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and Preferred Term.
Additional summaries will present the number (percentage) of subjects with any adverse events by severity and by relationship to study vaccine; parameters evaluable by the Aeras 404 Pediatric Toxicity Table provided in the protocol, will be summarized by severity corresponding to Toxicity Grade, as appropriate.
|
Subjects will be followed for up to 1 year and 4 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigate the safety of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants
Time Frame: Subjects will be followed for up to 1 year and 4 months.
|
The number and percentage of subjects who are enrolled into the three-dose regimen (Cohorts 4-6) with solicited and unsolicited AEs (including serious adverse events [SAEs], local and systemic reactions, and clinical laboratory values or vital sign values recorded as newly abnormal following study vaccination) recorded post-vaccination will be summarized to address the secondary safety objective of the study.
Subjects in Cohorts 4 and 5 will be followed for : 1 year and 3 months, Cohort 6: 1 year 4 months and Solicited adverse events are captured 28 days post each vaccination.
|
Subjects will be followed for up to 1 year and 4 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the immunogenicity of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants.
Time Frame: Subjects will be followed for up to 1 year and 4 months.
|
T-cell response, as measured by Intracellular Cytokine Staining (ICS) following stimulation with peptide pools spanning the vaccine antigens, will be used to assess immunogenicity.
|
Subjects will be followed for up to 1 year and 4 months.
|
Select an appropriate dose regimen for AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants.
Time Frame: After all subjects in Cohorts 4 and 5 have completed Study Day 126, the safety and immunogenicity data from these Cohorts will be evaluated. The data will inform the decision on the study vaccine dose for Cohort 6.
|
Safety and immunogenicity analyses will be reviewed for the selection of the appropriate dose regimen
|
After all subjects in Cohorts 4 and 5 have completed Study Day 126, the safety and immunogenicity data from these Cohorts will be evaluated. The data will inform the decision on the study vaccine dose for Cohort 6.
|
Explore interactions between AERAS-404 and EPI vaccines.
Time Frame: Antibody concentration blood samples taken when subjects reach 12 months of age for all Cohorts and in addition, 28 post second study vaccine dose (Study Day 56) for subjects in Cohort 6 only.
|
Antibody concentration levels at 12 months of age for all Cohorts, and in addition at 28 days post second study vaccine dose (Study Day 56) for Cohort 6 will be presented.
Summaries will include antibody titers to Tetanus toxoid vaccine (tetanus; given at 6, 10, 14 weeks of age), and Haemophilus influenza B conjugate vaccine (given at 6, 10, 14 weeks of age).
Responses to other EPI vaccines may also be assessed.
|
Antibody concentration blood samples taken when subjects reach 12 months of age for all Cohorts and in addition, 28 post second study vaccine dose (Study Day 56) for subjects in Cohort 6 only.
|
Assess the immunogenicity of a 2-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants.
Time Frame: Subjects will have Immunology samples taken at multiple time points for up to 1 year and 4 months.
|
Subjects will have Immunology samples taken at multiple time points for up to 1 year and 4 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Ann Ginsberg, MD, PhD, Aeras
- Principal Investigator: Avy Violari, MD, Perinatal HIV Research Unit
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2013
Primary Completion (ACTUAL)
December 22, 2017
Study Completion (ACTUAL)
December 22, 2017
Study Registration Dates
First Submitted
May 21, 2013
First Submitted That Met QC Criteria
May 22, 2013
First Posted (ESTIMATE)
May 24, 2013
Study Record Updates
Last Update Posted (ACTUAL)
April 9, 2018
Last Update Submitted That Met QC Criteria
April 6, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-015-404/ IMPAACT P1113
- U01AI068632 (U.S. NIH Grant/Contract)
- C-015-404 (OTHER: Aeras)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on AERAS-404
-
AerasStatens Serum InstitutCompletedTuberculosisSouth Africa
-
AerasStatens Serum InstitutCompleted
-
AerasStatens Serum InstitutCompleted
-
AerasSanofi Pasteur, a Sanofi CompanyCompleted
-
AerasSanofi Pasteur, a Sanofi CompanyCompleted
-
AerasEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Completed
-
University of OxfordCrucell Holland BV; University of Birmingham; Emergent BioSolutions; AerasCompleted
-
AerasCrucell Holland BVCompletedTuberculosisSouth Africa
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AerasStatens Serum InstitutCompleted